@article{ATM5792,
author = {Lorenza Landi and Federico Cappuzzo},
title = {Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer},
journal = {Annals of Translational Medicine},
volume = {3},
number = {3},
year = {2015},
keywords = {},
abstract = {Since the identification of epidermal growth factor receptor mutations (EGFRmut+), biomarker selection of patients for specific targeted agents became the standard of care in advanced non-small-cell lung cancer (NSCLC). Small molecules against the tyrosine kinase domain of EGFR (EGFR TKIs) such as gefitinib, erlotinib or afatinib, induced impressive and durable responses in patients with EGFRmut+, demonstrating superiority over platinum-based chemotherapy when used in front-line setting (1-3).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/5792}
}